Which medications in the drug class Transthyretin Binders are used in the treatment of Cardiac Amyloidosis?

Updated: Mar 25, 2020
  • Author: Gyanendra K Sharma, MD, FACC, FASE; Chief Editor: Terrence X O'Brien, MD, MS, FACC  more...
  • Print
Answer

Transthyretin Binders

Accumulation of amyloid fibrils composed of misfolded transthyretin protein in the heart leads to transthyretin amyloid cardiomyopathy and heart failure. Drugs that stabilize the amyloidogenic process may slow disease progression.

Tafamidis (Vyndamax)

Tafamidis is indicated for cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. Tafamidis is a selective stabilizer of TTR. Tafamidis binds to TTR at thyroxine binding sites, stabilizing the tetramer and slowing dissociation into monomers, the rate-limiting step in the amyloidogenic process. NOTE: Tafamidis and tafamidis meglumine are not interchangeable on a mg-per-mg basis.

Tafamidis meglumine (Vyndaqel)

Tafamidis meglumine is indicated for cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. Tafamidis is a selective stabilizer of TTR. Tafamidis binds to TTR at thyroxine binding sites, stabilizing the tetramer and slowing dissociation into monomers, the rate-limiting step in the amyloidogenic process. NOTE: Tafamidis and tafamidis meglumine are not interchangeable on a mg-per-mg basis.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!